Welcome to our dedicated page for Anixa Biosciences SEC filings (Ticker: ANIX), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Anixa Biosciences, Inc. filings document regulatory disclosures for a cancer-focused biotechnology company developing vaccine and CAR-T therapy programs. Recent Form 8-K reports include Regulation FD disclosures on the company's ovarian cancer CAR-T program, lira-cel, and its investigational breast cancer vaccine, including related press releases and scientific-presentation exhibits.
The company's proxy and annual-meeting filings cover board elections, advisory executive-compensation votes, auditor ratification, common-stock voting results, and other governance matters. These filings provide the formal record for Anixa's public-company reporting around clinical-program updates, stockholder actions, and corporate oversight.
Form 4 filing overview: On 07/11/2025, Anixa Biosciences (ANIX) Chief Executive Officer Amit Kumar executed an open-market purchase (Code “P”) of 5,000 common shares at $3.15 per share, an aggregate value of roughly $15,750.
Following the transaction, Kumar’s direct ownership increased to 574,925 shares. No derivative securities were reported and the filing was submitted as a single-person report on 07/14/2025.
The purchase represents a ~0.9% increment to Kumar’s previously held position and signals a modest vote of confidence from the company’s most senior executive. However, given the limited dollar amount relative to both his existing stake and the company’s overall share count, the transaction is unlikely to be viewed as a materially game-changing event by the market.